Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.56 |
| ▸ | MERTK | Q12866 | 6/20 | 0.54 |
| ▸ | AXL | P30530 | 5/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488733 | 1.00 | MET (0.56) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217527 | 0.92 | MET (0.57) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10379635 | 0.91 | MET (0.57) | METATRMAP4K4 | |
| SCHEMBL10218036 | 0.90 | MET (0.55) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217770 | 0.90 | MET (0.59) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL488391 | 0.90 | MET (0.68) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL30453080 | 0.90 | MET (0.68) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217423 | 0.89 | MET (0.54) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL10217914 | 0.88 | MET (0.55) | METMERTKAXLAVPR2AVPR1A | |
| SCHEMBL488613 | 0.88 | MET (0.66) | METMERTKAXLAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |